A recent study published in the journal Obesity highlights the differences in weight loss outcomes between patients using GLP-1 medications, such as semaglutide (Wegovy) and tirzepatide (Zepbound), in real-world settings compared to clinical trials. The findings indicate that individuals in everyday situations generally experience less weight loss and more frequent discontinuation of these medications than those participating in controlled trials.
Researchers analyzed health records of 7,881 adults with obesity, focusing on those who did not have type 2 diabetes and were seen at the Cleveland Clinic from 2021 to 2023. The study revealed that around 50% of participants stopped using their prescribed medications within the first year, a stark contrast to the 14-17% discontinuation rates seen in clinical trials. Additionally, the average weight loss after one year for semaglutide users in the real world was approximately 8%, compared to 15% in clinical trials. For tirzepatide, the figures were 12% versus 20% for higher doses in trials.
The researchers noted that many individuals used lower doses of their medications outside trial settings, which may contribute to reduced efficacy. Despite lower weight loss, it was observed that participants did not regain weight as rapidly as those in clinical trials, suggesting a potential benefit in longer-term weight maintenance.
Experts emphasized the importance of lifestyle changes, such as diet and exercise, alongside medication use for effective weight management. They pointed out that real-life challenges, including medication costs and side effects, can hinder adherence to treatment regimens. The study underscores the need for ongoing research into the factors influencing treatment discontinuation and the integration of behavioral strategies in obesity management.